FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3193797368> ?p ?o ?g. }

• W3193797368 endingPage "S103" @default.
• W3193797368 startingPage "S102" @default.
• W3193797368 abstract "Objectives: High-grade serous ovarian cancer (HGSOC) is the leading cause of death from gynecological cancer in the US. The majority of patients will present at advanced stage and will recur due to chemoresistance. New therapeutic strategies such as epigenetic and cannabinoid-based therapies may help circumvent this chemoresistance problem. We aim to determine the potency of clinically relevant concentrations of CBD monotherapy as well as combined with epigenetic (ET) and classic chemotherapy on tumor formation and propagation in 3-Dimensional (3D) ovarian cancer (OC) spheroid models. Methods: We created our clinically relevant 3D spheroid tissue culture model in order to mimic physiological conditions in vivo with platinum sensitive OC cell lines. Spheroids were treated with both one time and chronic doses of cannabidiol (CBD) at pre-determined concentrations alone or in combination with chemotherapeutic and epigenetic drugs (Cisplatin/Paclitaxel, Panobinostat). Spheroid growth and morphology were evaluated over an extended time kinetic (days 0, 3, 6, 10/12) and measured by volume of growth. The average radius of the spheroids was used to calculate the spheroid volume according the formula V = 4/3 πr3 and was monitored for percent growth relative to spheroid size at the beginning of the experiment (day 0). Microscopic pictures were taken to follow the morphologic changes. Results: Over an extended kinetic, high and medium concentrations of one time CBD (CBDH) tended to stunt spheroid growth in comparison to control, (686% and over 700% less growth). Low concentrations of one time CBD (CBDL) had a lessened effect on spheroid growth, (556% less growth). Classic chemotherapy combined with CBD contributed to a decreased overall spheroid growth, and even shrinkage with one time CBDL (34% shrinkage versus 84% growth in C/T group) over an extended kinetic. Chronic CBDH administration resulted in greater than 7500% less growth by day 10. Chronic CBDL in combination with C/T resulted in a 99% less growth in comparison to C/T by day 6. One time CBD administration with Panobinostat (Pano) decreased the amount of growth over a shorter kinetic (18% and 2% shrinkage for Pano/CBDL and Pano/CBDM, respectively, versus 13% growth for Pano). With the application of chronic CBD, Pano and CBD resulted in shrinkage early on and even 100% lysis of 3D OC by day 10. Conclusions: As demonstrated by our results, clinically relevant concentrations of CBD possess antitumorigenic effects on OC cells. Further, our data using the combination of Panobinostat with varying concentrations of CBD leads us to hypothesize that a one-time dose of CBD is not sufficient for prolonged antitumorigenic effects, with a synergistic effect demonstrated by chronic administration of CBD. Regarding classic chemotherapy and the effect of varying concentrations of CBD, our data indicates a synergistic effect exists with low concentrations of CBD. Further studies are indicated to determine whether these synergistic effects can aid in the reversal of chemoresistance and enhance the efficacy of targeted treatments. High-grade serous ovarian cancer (HGSOC) is the leading cause of death from gynecological cancer in the US. The majority of patients will present at advanced stage and will recur due to chemoresistance. New therapeutic strategies such as epigenetic and cannabinoid-based therapies may help circumvent this chemoresistance problem. We aim to determine the potency of clinically relevant concentrations of CBD monotherapy as well as combined with epigenetic (ET) and classic chemotherapy on tumor formation and propagation in 3-Dimensional (3D) ovarian cancer (OC) spheroid models. We created our clinically relevant 3D spheroid tissue culture model in order to mimic physiological conditions in vivo with platinum sensitive OC cell lines. Spheroids were treated with both one time and chronic doses of cannabidiol (CBD) at pre-determined concentrations alone or in combination with chemotherapeutic and epigenetic drugs (Cisplatin/Paclitaxel, Panobinostat). Spheroid growth and morphology were evaluated over an extended time kinetic (days 0, 3, 6, 10/12) and measured by volume of growth. The average radius of the spheroids was used to calculate the spheroid volume according the formula V = 4/3 πr3 and was monitored for percent growth relative to spheroid size at the beginning of the experiment (day 0). Microscopic pictures were taken to follow the morphologic changes. Over an extended kinetic, high and medium concentrations of one time CBD (CBDH) tended to stunt spheroid growth in comparison to control, (686% and over 700% less growth). Low concentrations of one time CBD (CBDL) had a lessened effect on spheroid growth, (556% less growth). Classic chemotherapy combined with CBD contributed to a decreased overall spheroid growth, and even shrinkage with one time CBDL (34% shrinkage versus 84% growth in C/T group) over an extended kinetic. Chronic CBDH administration resulted in greater than 7500% less growth by day 10. Chronic CBDL in combination with C/T resulted in a 99% less growth in comparison to C/T by day 6. One time CBD administration with Panobinostat (Pano) decreased the amount of growth over a shorter kinetic (18% and 2% shrinkage for Pano/CBDL and Pano/CBDM, respectively, versus 13% growth for Pano). With the application of chronic CBD, Pano and CBD resulted in shrinkage early on and even 100% lysis of 3D OC by day 10. As demonstrated by our results, clinically relevant concentrations of CBD possess antitumorigenic effects on OC cells. Further, our data using the combination of Panobinostat with varying concentrations of CBD leads us to hypothesize that a one-time dose of CBD is not sufficient for prolonged antitumorigenic effects, with a synergistic effect demonstrated by chronic administration of CBD. Regarding classic chemotherapy and the effect of varying concentrations of CBD, our data indicates a synergistic effect exists with low concentrations of CBD. Further studies are indicated to determine whether these synergistic effects can aid in the reversal of chemoresistance and enhance the efficacy of targeted treatments." @default.
• W3193797368 created "2021-08-30" @default.
• W3193797368 creator A5022001569 @default.
• W3193797368 creator A5027400658 @default.
• W3193797368 creator A5037344768 @default.
• W3193797368 creator A5043277917 @default.
• W3193797368 date "2021-08-01" @default.
• W3193797368 modified "2023-09-26" @default.
• W3193797368 title "Cannabidiol suppresses 3-dimensional ovarian cancer growth and may enhance potency of classic and epigenetic therapies" @default.
• W3193797368 doi "https://doi.org/10.1016/s0090-8258(21)00838-6" @default.
• W3193797368 hasPublicationYear "2021" @default.
• W3193797368 type Work @default.
• W3193797368 sameAs 3193797368 @default.
• W3193797368 citedByCount "1" @default.
• W3193797368 countsByYear W31937973682022 @default.
• W3193797368 crossrefType "journal-article" @default.
• W3193797368 hasAuthorship W3193797368A5022001569 @default.
• W3193797368 hasAuthorship W3193797368A5027400658 @default.
• W3193797368 hasAuthorship W3193797368A5037344768 @default.
• W3193797368 hasAuthorship W3193797368A5043277917 @default.
• W3193797368 hasConcept C104317684 @default.
• W3193797368 hasConcept C118552586 @default.
• W3193797368 hasConcept C121608353 @default.
• W3193797368 hasConcept C126322002 @default.
• W3193797368 hasConcept C143998085 @default.
• W3193797368 hasConcept C175369904 @default.
• W3193797368 hasConcept C202751555 @default.
• W3193797368 hasConcept C207001950 @default.
• W3193797368 hasConcept C2776694085 @default.
• W3193797368 hasConcept C2776895053 @default.
• W3193797368 hasConcept C2777056318 @default.
• W3193797368 hasConcept C2777292972 @default.
• W3193797368 hasConcept C2778239845 @default.
• W3193797368 hasConcept C2778305200 @default.
• W3193797368 hasConcept C2780225316 @default.
• W3193797368 hasConcept C2780427987 @default.
• W3193797368 hasConcept C2781100745 @default.
• W3193797368 hasConcept C2781451048 @default.
• W3193797368 hasConcept C41091548 @default.
• W3193797368 hasConcept C502942594 @default.
• W3193797368 hasConcept C54355233 @default.
• W3193797368 hasConcept C57992300 @default.
• W3193797368 hasConcept C64927066 @default.
• W3193797368 hasConcept C71924100 @default.
• W3193797368 hasConcept C81885089 @default.
• W3193797368 hasConcept C86803240 @default.
• W3193797368 hasConcept C98274493 @default.
• W3193797368 hasConceptScore W3193797368C104317684 @default.
• W3193797368 hasConceptScore W3193797368C118552586 @default.
• W3193797368 hasConceptScore W3193797368C121608353 @default.
• W3193797368 hasConceptScore W3193797368C126322002 @default.
• W3193797368 hasConceptScore W3193797368C143998085 @default.
• W3193797368 hasConceptScore W3193797368C175369904 @default.
• W3193797368 hasConceptScore W3193797368C202751555 @default.
• W3193797368 hasConceptScore W3193797368C207001950 @default.
• W3193797368 hasConceptScore W3193797368C2776694085 @default.
• W3193797368 hasConceptScore W3193797368C2776895053 @default.
• W3193797368 hasConceptScore W3193797368C2777056318 @default.
• W3193797368 hasConceptScore W3193797368C2777292972 @default.
• W3193797368 hasConceptScore W3193797368C2778239845 @default.
• W3193797368 hasConceptScore W3193797368C2778305200 @default.
• W3193797368 hasConceptScore W3193797368C2780225316 @default.
• W3193797368 hasConceptScore W3193797368C2780427987 @default.
• W3193797368 hasConceptScore W3193797368C2781100745 @default.
• W3193797368 hasConceptScore W3193797368C2781451048 @default.
• W3193797368 hasConceptScore W3193797368C41091548 @default.
• W3193797368 hasConceptScore W3193797368C502942594 @default.
• W3193797368 hasConceptScore W3193797368C54355233 @default.
• W3193797368 hasConceptScore W3193797368C57992300 @default.
• W3193797368 hasConceptScore W3193797368C64927066 @default.
• W3193797368 hasConceptScore W3193797368C71924100 @default.
• W3193797368 hasConceptScore W3193797368C81885089 @default.
• W3193797368 hasConceptScore W3193797368C86803240 @default.
• W3193797368 hasConceptScore W3193797368C98274493 @default.
• W3193797368 hasLocation W31937973681 @default.
• W3193797368 hasOpenAccess W3193797368 @default.
• W3193797368 hasPrimaryLocation W31937973681 @default.
• W3193797368 hasRelatedWork W1993880164 @default.
• W3193797368 hasRelatedWork W2020778541 @default.
• W3193797368 hasRelatedWork W2072767112 @default.
• W3193797368 hasRelatedWork W2105623825 @default.
• W3193797368 hasRelatedWork W2157919202 @default.
• W3193797368 hasRelatedWork W2320097775 @default.
• W3193797368 hasRelatedWork W2417634857 @default.
• W3193797368 hasRelatedWork W2590297198 @default.
• W3193797368 hasRelatedWork W2968124559 @default.
• W3193797368 hasRelatedWork W4238509468 @default.
• W3193797368 hasVolume "162" @default.
• W3193797368 isParatext "false" @default.
• W3193797368 isRetracted "false" @default.
• W3193797368 magId "3193797368" @default.
• W3193797368 workType "article" @default.